Axsome Therapeutics FY Conference Summary Company Overview - **Company**: Axsome Therapeutics (NasdaqGM:AXSM) - **Date of Conference**: March 02, 2026 - **Key Personnel**: COO Mark Jacobson, CFO Nick Pizzie Core Business and Financial Performance - **AUVELITY Performance**: Generated $155 million in the last quarter, annualizing over $600 million after 13 quarters from launch [3][4] - **Sales Force Expansion**: Plans to increase field force from 300 to 600 representatives to enhance market penetration, particularly in anticipation of Alzheimer's disease agitation [3][4] - **Operating Leverage**: Revenues outpaced operating expenses by a ratio of 3:1 in 2025, with expectations for continued leverage in 2026 [4] Product Pipeline and Development - **Robust Pipeline**: Currently has 5 product candidates across 9 indications, with AXS-05 for Alzheimer's disease agitation being a key focus [5] - **PDUFA Date**: AXS-05 has a PDUFA date set for April 30, 2026, with pre-launch activities already underway [5][12] - **Clinical Trials**: Positive results from randomized withdrawal studies and head-to-head placebo-controlled studies for AXS-05, with significant safety data collected [15][16] Market Insights - **Market Penetration**: Currently at 0.2% of the total antidepressant market, indicating substantial growth potential [8] - **Patient Demographics**: Over 7 million Alzheimer's patients in the U.S., with an estimated 70% experiencing agitation, representing a significant treatment opportunity [20] - **Direct-to-Consumer Campaign**: Launched a national DTC campaign in September, with plans to continue through 2026, aiming to enhance product adoption [10][11] Competitive Landscape - **Comparison with Rexulti**: Acknowledged as the only approved product for Alzheimer's agitation, but differences in mechanism and sales strategy noted [31][32] - **Market Access**: Anticipated 100% coverage in government channels for Alzheimer's agitation, similar to MDD, which could facilitate script writing [34] Additional Products and Future Opportunities - **Simbravo Launch**: Targeted approach with a sales team focused on headache centers, showing early positive feedback [35][36] - **AXS-12 for Narcolepsy**: NDA submission expected soon, with peak sales potential estimated between $500 million to $1 billion [40][42] - **Sunosi Expansion**: Positive Phase 3 data in adult ADHD, with plans for pediatric studies, indicating a significant market opportunity [43][44] - **AXS-14 for Fibromyalgia**: Currently conducting a new study following an RTF from the FDA, with expectations for compelling data in an underserved market [51][53] Conclusion - Axsome Therapeutics is positioned for significant growth with a robust pipeline and strategic expansions in sales force and market access. The upcoming PDUFA date for AXS-05 and ongoing clinical trials for other products highlight the company's commitment to addressing unmet medical needs in various therapeutic areas.

Summary of Neumora Therapeutics Conference Call Company Overview - **Company**: Neumora Therapeutics (NasdaqGS: NMRA) - **Event**: Guggenheim Emerging Outlook Biotech Summit, 2026 - **Date**: February 11, 2026 Key Points Industry and Product Focus - Neumora is focused on developing NMRA-511, a treatment for agitation in Alzheimer's disease (AD) [2][3] - The company is also exploring NLRP3 inhibitors for obesity and other indications [24][26] Clinical Data and Efficacy - NMRA-511 showed a significant clinical effect in a phase 1B study for AD agitation, achieving a 20.1-point reduction on the CMAI total score at week 8, with a Cohen's D effect size of 0.51-0.64 [5] - The CMAI aggression subfactor score for elevated anxiety populations had a robust effect size of 0.82 [6] - The CGI-S agitation score indicated a clinical effect size of 0.78 at week 6 and 0.38 at week 8, supporting the drug's potential [7] - NMRA-511 demonstrated a favorable safety and tolerability profile, allowing for higher dose testing planned for 2026 [8] Future Development Plans - Neumora plans to initiate a MAD extension cohort for NMRA-511 in 2026, transitioning to a QD extended-release formulation [9] - A pivotal phase 2/3 program is expected to start in 2027 [9] Market Opportunity - Approximately 60%-70% of Alzheimer's patients experience agitation and anxiety, indicating a significant market opportunity for NMRA-511 [10][11] - The company aims to enrich patient populations in pivotal studies to enhance treatment efficacy [11] Competitive Landscape - Competitors include Newleos and Azevan, which are also exploring treatments for anxiety and agitation [19] - Neumora's NMRA-511 is positioned as having a differentiated efficacy and safety profile compared to existing treatments like REXULTI and AUVELITY [8] Safety and Tolerability - No significant safety concerns were reported, with only minor cases of headache and one SAE related to hyponatremia deemed confounded by other factors [21][22] Financial Position - Neumora's current cash position is expected to support operations into the third quarter of 2027, covering all discussed catalysts [48] Other Programs - Neumora is advancing two M4 PAM compounds (NMRA-861 and NMRA-898) in phase 1 studies, with updates expected mid-2026 [40][44] - The company is also working on the KOASTAL program for navacaprant, with data readouts expected in the second quarter of 2026 [45][47] Conclusion Neumora Therapeutics is making significant strides in developing NMRA-511 for Alzheimer's disease agitation, with promising clinical data and a clear path for future studies. The company is well-positioned in a growing market, with a solid financial foundation to support its ongoing and future programs.

Axsome Therapeutics (AXSM) Conference Call Summary Company Overview - Axsome Therapeutics is a commercial-stage company focused on Central Nervous System (CNS) indications with several approved products and a broad pipeline [1][2] Key Financial Performance - Q1 2025 net sales reached $120 million, with $96 million from OVALITY (for major depressive disorder) and $25 million from Sunosi [4][5] Product Launches and Pipeline - Symbravo, for acute treatment of migraine, is set to launch next month [5][6] - AXS-05 for Alzheimer's disease agitation is on track for an sNDA submission in Q3 2025 [6][18] - Positive data readouts for solriamfetol in ADHD and major depressive disorder with excessive daytime sleepiness [7][39] Market Adoption and Sales Strategy - OVALITY has over 50% adoption as a first or second-line treatment in major depressive disorder [9] - The sales team has expanded to approximately 300 account managers, with expectations for growth in the commercial channel [10][11] - The company aims for over 80-85% of lives covered in the antidepressant class [11][12] Competitive Advantages - OVALITY is noted for its rapid onset of action, durability, and favorable safety profile compared to traditional antidepressants [14][15] - AXS-05 is differentiated from atypical antipsychotics, which have a black box warning for elderly patients with dementia [23][24] Clinical Development Highlights - Three positive trials completed for AXS-05 in Alzheimer's agitation, with no safety signals for falls or mortality [17][18] - The company is preparing for NDA submissions for AXS-14 (fibromyalgia) and AXS-12 (cataplexy in narcolepsy) [45][46] Future Outlook - Axsome anticipates significant growth and attention as more products come into focus, particularly with ongoing regulatory filings and launches [47][48]